This study investigated the molecular and phenotypic characteristics of carbapenemase-producing Klebsiella pneumoniae, and identified the risk factors underlying its acquisition. We evaluated K. pneumoniae isolated in Nagasaki University Hospital between January 2009 and June 2015. The presence of carbapenemase genes and plasmid characteristics were investigated. We performed multilocus sequence typing (MLST), and generated a dendrogram based on the results of pulsed-field gel electrophoresis (PFGE) for carbapenemase-producing strains. We also performed a case-control study of patients.
Introduction
Klebsiella pneumoniae is an important pathogen of various infections such as pneumonia, biliary and urinary tract infections, and bacteremia [1e4] . Until recently, carbapenems were one of the most reliable antimicrobials for treating infections caused by K. pneumoniae including extended-spectrum b-lactamase-producing strains; however, the prevalence of carbapenem-resistant K. pneumoniae is increasing worldwide. Plasmid-mediated carbapenemase producers are especially problematic because plasmids harboring resistant genes transfer among different bacterial genera or species [5e7] .
There are many types of carbapenemases found on plasmids such as K. pneumoniae carbapenemases (KPCs), OXA-b-lactamases, and metallo-b-lactamases (MBLs) including New Delhi MBL (NDM), Verona integron-encoded MBL (VIM), and IMP-type MBL [8, 9] . The outbreaks by KPC-, NDM-, and VIM-type carbapenemase-producers have been reported in Europe and KPCs are the most prevalent carbapenemases in the United States [5, 6] . In Japan, IMP-type MBLs, especially IMP-1, are widespread [10e12] .
The Japan Nosocomial Infections Surveillance (JANIS), a program of the Ministry of Health Labour and Welfare, reported in 2016 that 0.2% and 0.5% of K. pneumoniae are resistant to imipenem and meropenem according to the Clinical and Laboratory Standard Institute (CLSI) definitions, respectively [13] . These resistant rates for carbapenems are not currently high. However, in addition to dissemination of IMP-1, IMP-6-producing K. pneumoniae, which are susceptible to imipenem but resistant to meropenem, have newly emerged in recent years in the western part of Japan [14] . Furthermore, a recent report noted that the resistance rates to imipenem and meropenem in Enterobacteriaceae are stably increasing and that Klebsiella spp. accounted for the largest population of carbapenemresistant Enterobacteriaceae (CRE) in Asia [7] .
In contrast to European countries and the United States, the epidemiological characteristics of carbapenemase-producing K. pneumoniae have not been fully investigated in Japan. Therefore, we conducted molecular and phenotypic analyses of carbapenemase-producing K. pneumoniae isolated in our hospital. Additionally, we performed a case-control study of patients to identify risk factors for the acquisition of carbapenemaseproducing K. pneumoniae.
Patients and methods

Screening of bacterial strains
We retrospectively investigated K. pneumoniae isolated in Nagasaki University Hospital between January 2009 and June 2015. Strains for which minimum inhibitory concentrations (MICs) were 1 mg/mL for imipenem and/or meropenem were extracted from the database for further analyses. We measured MICs using the BD Phoenix Automated Microbiology System (BD Diagnostics). Drug susceptibility results were interpreted according to the CLSI M100-S28 [15] . For case-control studies, if strains were repeatedly identified from a single patient during the study period, de-duplication was performed and the first isolated strain was included. This process was performed regardless of specimen type.
Detection of carbapenemase genes and production
We used PCR to evaluate the presence of IMP and KPC carbapenemase genes for strains with MIC 1 mg/mL for imipenem and/ or meropenem. DNA was extracted using the boiling method. Bacterial colonies were suspended in 100 mL Tris-EDTA buffer containing 250 U/mL achromopeptidase (Wako Pure Chemical Industries, Ltd.), and were incubated at 50 C for 10 min. After adding 250 mL of
10% Chelex
® 100 Resin (Bio-Rad), the suspension was boiled at 99 C for 5 min, cooled on ice for 1 min, and centrifuged at 12,000 rpm for 1 min. Then the supernatant was harvested and used as a template for PCR amplification. PCR primers to amplify IMP and KPC genes were as follows: IMP forward, 5 0 -GGAATAGAGTGGCTTAAYTCTC-3'; IMP reverse, 5 0 -GGTTTAAYAAAACAACCACC-3'; KPC forward, 5 0 -CGTCTAGTTCTGCTGTCTTG-3'; KPC reverse, 5 0 -CTTGTCATCCTTGT-TAGGCG-3' [2] . PCR amplification was performed under the following conditions: 10 min at 94 C, 40 cycles consisting of 30 s at 94 C, 40 s at 52 C, 1 min at 72 C, and 5 min at 72 C for the final extension. DNA fragments were analyzed by electrophoresis on a 1.5% agarose gel. If IMP-type MBL was detected, direct sequencing was performed using the ABI PRISM 3130 Genetic Analyzer according to the manufacturer's instructions (Applied Biosystems) to differentiate between IMP-1 and IMP-6, which only differed by one base pair compared to IMP-1 [16] . Carbapenemase production was examined using the modified carbapenem inactivation method (mCIM) according to the CLSI M100-S28 [15] .
Analysis of plasmid characteristics
Plasmid incompatibility groups were determined using a PCRbased replicon typing kit (Diatheva), which can detect 25 major replicons by 8 multiplex PCRs, according to the manufacturer's instructions. Also, conjugal transfer of plasmid was evaluated. For bacterial conjugation, carbapenem-sensitive but quinoloneresistant Escherichia coli was used as a recipient. IMP-1-producing K. pneumoniae and a recipient were coincubated in LB broth at 30 C for 12e18 h and inoculated onto LB agar containing ciprofloxacin (35 mg/mL) and meropenem (25 mg/mL). After overnight incubation, bacteria grown were confirmed to be E. coli and the presence of IMP genes was evaluated by PCR.
Multilocus sequence typing
We performed multilocus sequence typing (MLST) for carbapenemase-producing strains, targeting seven housekeeping genes (rpoB, gapA, mdh, pgi, phoE, infB, and tonB) as previously described [17] . The allele sequences and sequence types (STs) were determined according to the Klebsiella MLST database (http://bigsdb. pasteur.fr/klebsiella/klebsiella.html).
Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) using the XbaI restriction enzyme was performed by Miroku Medical Laboratory Inc. according to the manufacturer's instructions and as described in the textbook with modifications [18] . A Dice coefficient-based dendrogram was generated according to the unweighted-pair group method with arithmetic mean (UPGMA) using Fingerprinting II Software Version 3.0 (Bio-Rad). The chromosomal DNA restriction patterns were interpreted according to the criteria as previously reported [19] .
Case-control study
We conducted a matched case-control study using a 1:3 case to control ratio to identify risk factors for the acquisition of carbapenemase-producing K. pneumoniae. Control patients (uninfected control) were selected among patients from whom carbapenemase producers had not been detected. The following matching parameters were used to select uninfected control: ward, year and month, and period at risk. The period at risk was defined as duration from admission to isolation of carbapenemase-producing strain for case patients, and as the total length of hospital stay for control patients, which was at least as long as that for the matched case patient. If the number of control patients who met the criteria was less than three patients because the length of hospital stay was shorter than the period at risk for the matched case, we selected controls in descending order of the length of hospital stay. If four or more patients for each case met the matching criteria, we selected control patients by random sampling using Excel (Microsoft Corporation). We chose this method to select control patients because previous reports have stated that this method provides the appropriate risk factors in a case-control study related to the acquisition of resistant bacteria [20e22] . We compared patient backgrounds between the case and control groups. We also analyzed the risk factors for acquiring carbapenemase-producing strains.
Statistical analysis
Matched univariate and multivariate analyses were performed using the conditional logistic regression model. Variables regarding comorbidities/conditions, use of medical devices, and prior antibiotic use with P values less than 0.05 in the univariate analysis were selected and adjusted by backward stepwise selection in the multivariate analysis to identify risk factors for acquisition of carbapenemase-producing strains. Data were analyzed using IBM SPSS statistics version 20, and P values of 0.05 were considered statistically significant.
Results
Bacterial strains, drug susceptibility, and carbapenemase detection
Of the 1462 K. pneumoniae strains isolated during the study period, 120 showed MIC 1 mg/mL for imipenem and/or meropenem, and 88 strains were available from our bacterial collection. We detected IMP-type MBL gene in 18 strains among the 88 strains examined. No KPC gene was detected. Sequencing analysis revealed that the 18 strains had the IMP-1-MBL gene but not the IMP-6 gene. Carbapenemase production was confirmed by mCIM in the 18 strains. The number of isolates peaked in 2012 (8 strains) and decreased thereafter. The results of drug susceptibilities are presented in Table 1 . Although no strain was susceptible to imipenem, one was susceptible to meropenem.
The MICs for amikacin were 4 mg/mL in all 18 strains. Only two strains were resistant to ciprofloxacin according to the CLSI definitions [15] .
Multilocus sequence typing
We submitted the new ST to the Klebsiella MLST database, which was defined as ST2603 (http://bigsdb.pasteur.fr/klebsiella/ klebsiella.html). Strains were divided into seven different STs by MLST (Fig. 1) , of which the most frequent type was ST1471 (six strains), followed by ST1148, ST1484, and ST2603 (three strains, respectively).
Pulsed-field gel electrophoresis
The similarity among strains was analyzed by a dendrogram based on the PFGE results. Three strains (KP15, KP16, and KP17) and three strains (KP1, KP3, and KP6) showed >80% similarity, respectively; and three strains (KP11, KP12, and KP14), two strains (KP1 and KP3), and six strains (KP4, KP5, KP7, KP8, KP9, and KP10) showed complete similarity (100%), respectively (Fig. 1) . We found relationships among PFGE patterns, STs, and the wards in which they were isolated, indicating the possibility that several strains were transmitted in the hospital.
Plasmid characteristics
IncL was the unique incompatibility group detected in the 17 IMP-producing K. pneumoniae. We could not determine the incompatibility group in one strain (KP13). Before the evaluation of conjugal transfer, all 18 IMP-producing K. pneumoniae and the recipient were cultured on LB agar containing only 35 mg/mL of ciprofloxacin. The recipient grew but 17 IMP-producing K. pneumoniae including KP10, which was a ciprofloxacin-resistant strain, did not grow on it, that meant that only recipient could be effectively selected. However, because KP18 grew on the agar containing only 35 mg/mL of ciprofloxacin, the conjugal transfer was not evaluated for the strain. Plasmid transfer was confirmed in 17 IMP-producing K. pneumoniae other than KP18 by conjugation. Table 2 shows details of 16 patients from whom IMP-1-producing K. pneumoniae was isolated. The median age and median duration from admission to isolation were 51.5 years old (interquartile range, 6.0e62.0) and 35.5 days (interquartile range, 25.0e42.5), respectively. Eleven patients (68.8%) were male. Eight strains were isolated from stool, followed by three strains from urine and ascites, and two strains from tracheal tube. One isolate (KP17) was detected by active screening. When the IMP-1 producer was isolated, nine patients were hospitalized in the A ward, five patients were in the B ward, and two patients were in the intensive care unit (ICU). Two patients from whom strains were isolated only Table 1 Results of the drug susceptibility of IMP-1 metallo-b-lactamase-producing Klebsiella pneumoniae.
Patient characteristics
Strain
Patient Year MIC (mg/ml) and susceptibility interpretation stayed in the ICU for 4 days, and had been hospitalized in the A ward before moving there. Of the 16 patients from whom IMP-1-producing K. pneumoniae was isolated, five patients developed infection such as respiratory infection and intra-abdominal infection. Multiple pathogens were simultaneously isolated in all five patients (Table 2) . Regarding treatment against infections caused by IMP-1 producers, patient 12 who developed respiratory infection was administered meropenem after treatment failure by ampicillin-sulbactam. Patients 2 and 13 with intra-abdominal infection received piperacillin-tazobactam. Patient 14, who also developed intra-abdominal infection, was treated with meropenem. These four patients improved and were discharged. Patient 9 with liver failure developed peritonitis caused by both drug-resistant Acinetobacter baumannii and K. pneumoniae producing IMP-1, and subsequently developed complications including pneumonia. Despite receiving antibiotic administration including meropenem, ciprofloxacin, and amikacin the patient ultimately died due to worsening of the general condition.
Risk factors for acquiring IMP-1-producing K. pneumoniae
Details of the case-control study and matched univariate analysis are presented in Table 3 . A total of 48 patients were matched as controls to 16 patients with IMP-1-producing K. pneumoniae. In the univariate analysis, age, ICU/neonatal intensive care unit (NICU) within 90 days, liver disease, administration of steroid/immunosuppressive agents, and prior uses of penicillin, third-generation cephalosporins, carbapenems, anti-methicillin-resistant Staphylococcus aureus (MRSA) drugs, and anti-fungal drugs were significant. In the multivariate analysis, seven variables with P values less than 0.05 in the univariate analysis and with regard to comorbidities/ conditions (liver disease, steroids/immunosuppressive agents) and prior antibiotic use (exposure to penicillins, third-generation cephalosporins, carbapenems, anti-MRSA drugs, and anti-fungal drugs) were selected and adjusted. Table 4 shows the matched multivariate analysis of risk factors for acquiring IMP-1-producing strains. Liver disease and previous uses of carbapenems and antifungal drugs were independent factors for acquiring IMP-1-producing strains.
Discussion
We demonstrated that IMP-1 MBL was the unique carbapenemase detected in K. pneumoniae in our hospital, with an incidence of only 1.2% among all K. pneumoniae isolated during the study period. However, several transmissions in the hospital . In this study, liver disease and previous uses of carbapenems and anti-fungal drugs were significant factors for acquiring IMP-1 producers. We could not find the previous report showing that exposure to anti-fungal drugs was a risk factor. It might reflect patient condition which needed anti-fungal therapy due to being under immunosuppression. Of the five patients who developed infection, one patient showed poor outcome due to severe liver failure and four patients improved. Because they were polymicrobial infection, there is a possibility that IMP-1 producer might have only colonized in those patients.
Specific STs such as ST258 and ST147 are reportedly high-risk clones associated with the international spread of carbapenemaseproducing K. pneumoniae [9, 26] . Of the seven different STs detected in this study, ST37 and ST443 have been reported to be associated with IMP-6-, KPC-, NDM-, and OXA-48-producing K. pneumoniae [27e32]. However, only a few of those strains were detected in this study. We could not find reports in the literature about ST1471, ST1484, ST1148, or ST2603, which were the most prevalent STs in our hospital. The relationships among them were not close with <50% similarity based on PFGE results. Conversely, plasmid incompatibility group was similar among the IMP-1 producers, and the plasmids were transferable. Further studies on those characteristics in major Enterobacteriaceae may be able to reveal plasmid transfer among different bacterial genera or species and its risk factors.
There were some limitations in this study. First, we selected strains for which the MICs for imipenem and/or meropenem were 1 mg/mL. It was difficult to detect all of the CPEs only using drug susceptibility because the MICs of CPE for carbapenems were sometimes <1 mg/mL [33, 34] . We could not analyze 32 strains that met the screening criteria but were not available for microbiological analysis. Additionally, since we evaluated only two major carbapenemases, we could not refer to other types of carbapenemases. Regarding the case-control study and analysis of risk factors, because our results might not apply to other institutions, respective hospitals should perform epidemiological evaluations to identify local factors.
In conclusion, we detected 18 carbapanemase-producing K. pneumoniae for 6.5 years in our hospital with IMP-1 MBL being the sole carbapenemase. We should recognize the possibility of transmission in hospital and risk factors for the acquisition of IMP-1-MBL-producing K. pneumoniae. Further evaluations are necessary to clarify regional epidemiology.
